rilmenidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, clonidine derivatives 2381 54187-04-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rilmenidine
  • oxaminozoline
  • rilmenidene
  • rilmenidine phosphate
  • rilmenidine dihydrogen phosphate
Oxazole derivative that acts as an agonist for ALPHA-2 ADRENERGIC RECEPTORS and IMIDAZOLINE RECEPTORS. It is used in the treatment of HYPERTENSION.
  • Molecular weight: 180.25
  • Formula: C10H16N2O
  • CLOGP: 1.42
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 33.62
  • ALOGS: -2.13
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.90 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 275.06 31.87 182 3483 227876 50373583
Lactic acidosis 242.72 31.87 91 3574 33264 50568195
Hyperkalaemia 135.15 31.87 67 3598 48022 50553437
Allergic reaction to excipient 103.63 31.87 18 3647 272 50601187
Mixed liver injury 76.82 31.87 22 3643 3429 50598030
Hyponatraemia 74.42 31.87 59 3606 96080 50505379
Rhabdomyolysis 71.68 31.87 41 3624 38986 50562473
Isosthenuria 68.66 31.87 11 3654 98 50601361
Pyelitis 63.03 31.87 11 3654 171 50601288
Bladder hypertrophy 60.99 31.87 11 3654 208 50601251
Electrocardiogram PR shortened 60.36 31.87 11 3654 221 50601238
Angioedema 52.11 31.87 33 3632 37643 50563816
Toxic skin eruption 51.38 31.87 22 3643 11229 50590230
Multiple organ dysfunction syndrome 47.94 31.87 35 3630 50302 50551157
Eye oedema 45.90 31.87 12 3653 1331 50600128
Creatinine renal clearance increased 44.82 31.87 10 3655 568 50600891
Carbohydrate antigen 15-3 increased 42.99 31.87 11 3654 1121 50600338
Carcinoembryonic antigen increased 40.11 31.87 11 3654 1463 50599996
Prevertebral soft tissue swelling of cervical space 39.53 31.87 6 3659 36 50601423
Peripheral artery haematoma 39.12 31.87 6 3659 39 50601420
Primary hyperaldosteronism 37.60 31.87 6 3659 52 50601407
Bradycardia 36.33 31.87 33 3632 64393 50537066
Intestinal transit time abnormal 36.05 31.87 6 3659 69 50601390
Psychomotor retardation 34.84 31.87 12 3653 3406 50598053
Cholestasis 34.49 31.87 22 3643 25379 50576080
Myoclonus 34.27 31.87 18 3647 14452 50587007
Fall 34.27 31.87 75 3590 334857 50266602
Renin decreased 34.27 31.87 6 3659 95 50601364
Overdose 34.13 31.87 39 3626 99688 50501771
Toxic encephalopathy 32.70 31.87 13 3652 5502 50595957

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 152.80 29.19 137 2038 265130 29307222
Lactic acidosis 63.93 29.19 35 2140 30212 29542140
Cerebral haematoma 63.36 29.19 20 2155 4276 29568076
Hyperkalaemia 52.07 29.19 40 2135 61352 29511000
Necrotising oesophagitis 51.30 29.19 11 2164 511 29571841
Hypovolaemic shock 49.06 29.19 18 2157 6054 29566298
Hemiplegia 33.61 29.19 14 2161 6580 29565772
Tubulointerstitial nephritis 30.70 29.19 18 2157 17625 29554727
Product name confusion 29.26 29.19 5 2170 67 29572285

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 376.85 25.18 317 5614 448923 64043878
Lactic acidosis 269.01 25.18 125 5806 61285 64431516
Hyperkalaemia 164.50 25.18 107 5824 101022 64391779
Allergic reaction to excipient 101.84 25.18 18 5913 234 64492567
Hyponatraemia 72.00 25.18 78 5853 148261 64344540
Isosthenuria 65.73 25.18 11 5920 101 64492700
Mixed liver injury 57.86 25.18 21 5910 5460 64487341
Electrocardiogram PR shortened 55.98 25.18 11 5920 261 64492540
Cerebral haematoma 55.82 25.18 22 5909 7163 64485638
Pyelitis 55.32 25.18 11 5920 278 64492523
Hypovolaemic shock 48.25 25.18 22 5909 10244 64482557
Bladder hypertrophy 47.99 25.18 11 5920 553 64492248
Angioedema 47.79 25.18 42 5889 61779 64431022
Pemphigoid 46.27 25.18 23 5908 12963 64479838
Necrotising oesophagitis 45.78 25.18 11 5920 679 64492122
Carbohydrate antigen 15-3 increased 41.87 25.18 11 5920 976 64491825
Rhabdomyolysis 40.58 25.18 46 5885 91680 64401121
Toxic skin eruption 40.34 25.18 24 5907 19260 64473541
Eye oedema 39.76 25.18 12 5919 1761 64491040
Creatinine renal clearance increased 38.53 25.18 10 5921 846 64491955
Prevertebral soft tissue swelling of cervical space 38.10 25.18 6 5925 36 64492765
Hypokalaemia 37.61 25.18 51 5880 121852 64370949
Peripheral artery haematoma 36.93 25.18 6 5925 45 64492756
Overdose 36.55 25.18 58 5873 159508 64333293
Multiple organ dysfunction syndrome 35.26 25.18 45 5886 101368 64391433
Hemiplegia 35.10 25.18 19 5912 12749 64480052
Carcinoembryonic antigen increased 34.91 25.18 11 5920 1862 64490939
Intestinal transit time abnormal 34.62 25.18 6 5925 69 64492732
Blood aldosterone increased 34.01 25.18 7 5924 211 64492590
Fall 32.63 25.18 98 5833 416728 64076073
Renin decreased 32.01 25.18 6 5925 110 64492691
Breast cancer recurrent 31.44 25.18 11 5920 2572 64490229
Renal failure 31.04 25.18 58 5873 181630 64311171
Primary hyperaldosteronism 31.01 25.18 6 5925 131 64492670
Intestinal haemorrhage 29.69 25.18 13 5918 5501 64487300
Myoclonus 27.69 25.18 21 5910 25097 64467704
Psychomotor retardation 27.29 25.18 12 5919 5131 64487670
Confusional state 26.96 25.18 68 5863 261076 64231725
Adenocarcinoma metastatic 26.41 25.18 5 5926 97 64492704
Hypochloraemia 25.94 25.18 9 5922 2052 64490749
Subdural haematoma 25.64 25.18 21 5910 28033 64464768

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AC06 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013565 Sympatholytics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR Ki 7.44 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 5.05 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 7.37 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 7.90 CHEMBL
Nischarin Membrane receptor Ki 7.23 CHEMBL
Nischarin Unclassified Ki 7.95 CHEMBL

External reference:

IDSource
D08482 KEGG_DRUG
85409-38-7 SECONDARY_CAS_RN
C0140591 UMLSCUI
CHEBI:8862 CHEBI
CHEMBL289480 ChEMBL_ID
DB11738 DRUGBANK_ID
D000077769 MESH_DESCRIPTOR_UI
68712 PUBCHEM_CID
5846 INN_ID
P67IM25ID8 UNII
236379 RXNORM
005772 NDDF
005773 NDDF
765332006 SNOMEDCT_US
765333001 SNOMEDCT_US

Pharmaceutical products:

None